PCSK9 and familial hypercholesterolemia: Proprotein convertase subtilisin kexin 9 (PCSK9) has attracted attention as a therapeutic target for patients with hypercholesterolemia due to its ability to reduce low-density lipoprotein cholesterol (LDL-C) levels [12].